Vanda Pharmaceuticals
VNDA
152 hedge funds and large institutions have $206M invested in Vanda Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 52 reducing their positions, and 20 closing their positions.
501% more call options, than puts
Call options by funds: $1.57M | Put options by funds: $261K
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
3% more funds holding
Funds holding: 148 → 152 (+4)
0.65% more ownership
Funds ownership: 74.8% → 75.45% (+0.65%)
10% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 52
16% less capital invested
Capital invested by funds: $246M → $206M (-$39.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.45M |
| 2 |
Goldman Sachs
New York
|
+$2.16M |
| 3 |
Millennium Management
New York
|
+$2.05M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.33M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.99M |
| 2 |
KAM
Krensavage Asset Management
New York
|
-$1.33M |
| 3 |
PIM
Profit Investment Management
North Bethesda,
Maryland
|
-$1.29M |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$910K |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$788K |
VNDA Hedge Fund Activity: Q3 2024 in Review
152 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2024, worth a combined $206M — down 16% from $246M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new VNDA positions and 20 closed out — a net gain of 5 holders — while 47 added to existing stakes and 52 trimmed.
The largest buyer was BlackRock, adding an estimated $2.45M. The largest seller was Nuveen, cutting an estimated $1.99M.
- 152 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2024, up from 148 in Q2 2024.
- Funds reported $206M of Vanda Pharmaceuticals stock for Q3 2024, down 16% quarter-over-quarter.
- 25 funds opened new Vanda Pharmaceuticals positions in Q3 2024 and 20 closed out, a net change of +5 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2024 was BlackRock, an estimated $2.45M added.
- The largest Vanda Pharmaceuticals seller in Q3 2024 was Nuveen, an estimated $1.99M sold.
Based on aggregated 13F filings for Q3 2024.